Current studies suggest that apolipoprotein E (apoE) genotype influences the rate of progression in Alzheimer's disease (AD), with patients carrying the e4 allele progressing faster than non-carriers. Results from some clinical trials show trends for apoE status and disease progression that disagree with trends in epidemiological studies however, raising questions as to whether populations defined for phase II clinical trials conform to the results seen in epidemiological studies, and raising concerns over the use of apoE genotyping as a progression-rate pharmacogenetic biomarker in AD diseasemodification trials. We examined the cognitive subset of the Alzheimer's Disease Assessment Scale (ADAS-Cog) from 436 placebo-treated patients who had been genotyped for the apoE e4 allele in two phase II clinical trials. In one trial e4 carriers showed a faster rate of decline (Po0.001) that was evident by 9 months after baseline; in the second trial e4 carriers showed worse cognitive scores at enrollment (Po0.05) and a trend towards a faster rate of cognitive decline, which reached borderline significance at 12 months (P ¼ 0.041). These results suggest that populations defined for clinical trials do in fact conform to the results seen in epidemiological studies, and studies showing a slower rate of disease progression in e4 carriers probably represent chance finding because of low power. Furthermore, we propose that apoE genotyping may be only useful as a diseaseprogression/stratification biomarker in larger studies, where one could expect 4219 e4 carriers per treatment group.
Clinical trials for disease-modification strategies in AD are necessarily long term, requiring patient follow-up for X1 year. In addition to the expense, patient drop-out and other problems associated with long-term follow-up, researchers designing these trials must deal with issues concerning the rate of cognitive decline, which differs substantially among individuals. 1 Pharmacogenetic biomarkers for AD, especially those predicting the rate of cognitive deterioration, are therefore of high interest in this area. If applied properly, these markers can increase the power of any given trial, and potentially reduce the number of subjects necessary. The ApoE e4 allele is the most obvious candidate, being both the most common and conferring the highest risk of any known genetic factor for late-onset AD. 2, 3 The literature is conflicting as to the effect of e4 on rate of cognitive decline; some studies show slower [4] [5] [6] whereas others faster rates. [7] [8] [9] [10] [11] This discrepancy may reflect chance findings because of a lack of power in smaller studies. Studies with over 200 AD subjects have consistently shown a more aggressive course of disease with the e4 allele, 7, 8, 10 and in the PROSPER trial (a large prospective study in the elderly with 5804 subjects) the e4 allele was associated both with poorer memory performance at baseline and with more rapid cognitive decline. 11 Nonetheless, smaller studies have generated some striking findings. For instance, the PPARg agonist rosiglitazone (RSG) was efficacious only in e4-negative patients, 12 making e4 genotype a candidate RSG responder/ non-responder biomarker for AD. Surprisingly, e4 allele carriers treated with placebo in this study showed a slower rate of cognitive decline than e4 non-carriers. Although this finding emerged in the context of potentially low power (n ¼ 78 on placebo), it raises the question as to whether cohorts defined for phase II clinical trials differ from those defined in academic and population-based studies. Conversely, it may suggest that trials with 35-50 subjects per genotype in each treatment group may be too small in which to do meaningful pharmacogenetic studies, even for genes with effects as large as the apoE alleles. To address these questions, we genotyped 436 placebo-treated patients for the common apoE alleles (e2, e3, e4) in two phase II AD disease-modification trials, and examined the associated rate of cognitive decline. Results for the e4 genotype are described here. ApoE e2 carriers were too rare (12 in Protocol 030 and 22 in Protocol 091) to be considered as a separate group; similarly they were evenly distributed among e4 carriers and non-carriers, thus these patients were included in the e4 analysis.
Two previous randomized clinical trials conducted by Merck were selected for this post hoc analysis: Protocol 091/rofecoxib (Table 1) and Protocol 030/MK-677 growth hormone secretagogue (Table 2 ). In the Protocol 030 trial, post hoc analysis suggested a possible beneficial effect of growth hormone secretagogue on AD progression rate in e4 non-carriers only 13 similar to the result seen with RSG treatment. In the rofecoxib study, however, conversion rate from mild cognitive impairment to AD was increased with rofecoxib treatment regardless of apoE genotype. 14, 15 Because the effect of treatment compounds and/or interaction with apoE genotype cannot be ruled out in either trial, only placebo-treated patients are examined here. To avoid issues in population stratification, only Caucasians were used in the present analysis.
The study design of the Protocol 030/growth hormone secretagogue trial has been described elsewhere. 13 Briefly, this was a 12-month randomized, double-blind, placebo-controlled trial which took place between November 2003 and January 2005. Patients were at least 50 years old, met criteria for probable AD, and had a Clinical Dementia Rating of 1 or 2 (mild-to-moderate severity) and a Mini Mental State Exam score between 14 and 26. Measurement of ADAS-Cog score was done at the screening visit (baseline) and on follow-up visits at 3, 6, 9, and 12 months.
The study design of the Protocol 091/Rofecoxib trial has been described elsewhere. 16 Briefly, this was a 12-month randomized, double-blind, placebo-controlled trial in which patients were enrolled between February and September of 1999. Patients were at least 50 years old, met criteria for possible or probable AD, and had a Clinical Dementia Rating no worse than moderate dementia and a Mini Mental State Exam score between 14 and 26. After a baseline measurement at randomization, ADAS-Cog was again measured on follow-up visits at 3, 6, 9, 12, 13.5 and 15 months.
DNA from patients in Protocol 030 and Protocol 091 trials was sent to Prevention Genetics for apoE genotyping.
Both groups (e4 carriers and non-carriers), showed a decrease in cognitive function as measured by ADAS-Cog score over the duration of the trials. In Protocol 091, a faster rate of decline was detected in e4 carriers by 9 months, and this trend continued at all later time points (Figure 1a) . In protocol 030 (Figure 1b) , the overall change in ADAS-Cog score for the combined patients groups over time was similar to that seen in Protocol 091. However, a faster decline in e4 carriers was detected at 12 months, and was borderline significant at that time point (P ¼ 0.041). Interestingly, although the mean baseline ADAS-Cog scores between the e4 carriers and non-carriers included in this analysis were similar in Protocol 091 (19.7 and 18.9, respectively), the e4 carriers in this analysis from Protocol 030 had worse mean baseline scores than the e4 non-carriers (22.6 vs 19.2, respectively; P ¼ 0.03). In fact, the average baseline ADAS-Cog score for all placebo-treated subjects was roughly two points higher in Protocol 030 than in Protocol 091. Therefore, it appears that in Protocol 030 patients were further progressed along the broad mild-to-moderate AD entry criteria used in both studies (MMSE of 14-26). If e4 carriers progress more rapidly as the population becomes more severe within a broad range, we should expect to see differences in baseline ADAS-Cog scores between e4 carriers and non-carriers in populations that are further progressed.
In summary, two trials having 4150 patients on placebo found the e4 genotype to be associated with faster decline in ADAS-Cog scores; addition- Based on the maximum observed genetic effect of apoE status as a biomarker for disease progression, these studies would have been powered at 50% (PN030) and 70% (PN091) in a standard clinical framework for Alzheimer's clinical trials. Although the studies presented here have borderline power for the purpose of using apoE as a biomarker for disease progression, these patient cohorts selected for double-blind clinical trials do in fact conform to what we see in the large population-based studies with respect to the effect of the e4 allele on the severity and course of AD. We therefore recommend that in studies with no100 per apoE subgroup (such as our Protocol 030) all pharmacogenetic results based on apoE genotyping should be interpreted with care. Findings in the literature of a slower or less severe form of AD associated with the e4 allele have thus far only come from small studies. Clinical trial populations are most likely not exceptions to this rule. The implications of these results for the use of apoE genotyping as a pharmacogenetic biomarker in phase II AD disease-modification trials although subtle are clearly important. Most large AD diseasemodification trials could benefit from apoE genotyping; this factor does appear to account for a variance in the rate of progression not captured by other characteristics such as baseline cognitive score. Thus, for trials in the near-term apoE genotyping is likely to be a useful method for controlling genetic variance in disease-progression rate. However, this generalization may only apply to large studies. When numbers are small the power appears to be too low, as studies of this size often fail to detect the effect of the e4 allele on disease progression consistently found in larger studies. Therefore, although apoE genotyping should enable more accurate estimates of treatment effects and potentially increase power in larger trials, it can have the paradoxical effect of weakening smaller trials, by causing the researchers to inappropriately divide subjects into several smaller, underpowered groups and hamper valid interpretation of any pharmacogenetic effects. This in turn can lead to erroneous conclusions concerning the efficacy of the compound/treatment in question, resulting in further costly (and unnecessary) trials in the case of a false positive, or the far worse case of delaying the development of a potential treatment for patients in the case of a false negative. The results presented here suggest that the findings by Risner et al.
12 may in fact be an example of this kind of error to the extent that the decision to move into phase III clinical trials was based on a chance finding from an underpowered pharmacogenetic analysis.
In summary, we have examined the effect of the e4 allele on cognition in AD, and found the e4 allele to be associated with faster decline in general, and to be associated with lower baseline scores in one trial. Our results are similar to those Only intention-to-treat and placebo/placebo patients included in analysis. ApoE e4+ patients showed significantly worse (higher) ADAS-Cog scores than e4-patients at baseline (P ¼ 0.03). The reason for this difference is unclear, patients were not genotyped until after completion of the trial.
found in the majority of large studies, suggesting a more severe course or form of AD with e4 presence. We propose, however, that it is only appropriate to use apoE genotype as a genetic biomarker in larger phase II trials, as the size of the effect of this allele on AD progression does not appear to be large enough to be meaningfully applied in small clinical trials.
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